×

drug_alert56quinine-methylene_blue_combination_risk_serious_adr.pdf

Home / Discover /www.who.int/medicines/publications/drugalerts/

  Parent Folder


drug_alert56quinine-methylene_blue_combination_risk_serious_adr.pdf
PDF 4 years ago 67.55 kB
Copy Link   
drug_alert57combination_barbiturate_product_hepatotoxicity.pdf
PDF 4 years ago 92.24 kB
Copy Link   
drug_alert55blood_products_withdrawn.pdf
PDF 4 years ago 65.67 kB
Copy Link   
drug_alert58blood_products_withdrawn.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert54terfenadine_proposed_withdrawal.pdf
PDF 4 years ago 87.13 kB
Copy Link   
drug_alert59diabetes_hyperglycaemia_with_protease_inhibitors.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert53chlormezanone_serious_cutaneous_reactions.pdf
PDF 4 years ago 75.68 kB
Copy Link   
drug_alert60gentamicin_ampoules_recall.pdf
PDF 4 years ago 59.92 kB
Copy Link   
drug_alert52update_diethylene_glycol_poisoning_children.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert61tilbroquinol_tilbroquinol-tiliquinol_risk_hepatotoxicity.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert51reports_haematomas_hiv_protease_inhibitors.pdf
PDF 4 years ago 63.86 kB
Copy Link   
drug_alert62arrowguard_recalled.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert50diethylene_glycol_poisoning_children.pdf
PDF 4 years ago 103.94 kB
Copy Link   
drug_alert63fenfluramine_dexfenfluramine_withdrawn.pdf
PDF 4 years ago 82.53 kB
Copy Link   
drug_alert49indication_restrictions_cyproterone_acetate.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert64pyrithione_zinc_topical_formulations_withdrawn_sale.pdf
PDF 4 years ago 87.89 kB
Copy Link   
drug_alert48defective_pacemakers.pdf
PDF 4 years ago 58.99 kB
Copy Link   
drug_alert65phenolphthalein_risk_carcinogenicity.pdf
PDF 4 years ago 65.34 kB
Copy Link   
drug_alert47naftidrofuryl_suspended.pdf
PDF 4 years ago 36.74 kB
Copy Link   
drug_alert66troglitazone_revised_prescribing_information.pdf
PDF 4 years ago 64.71 kB
Copy Link   

Join FilePursuit on FilePursuit Discord Server chat for discussions and more information.